Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Arts
  • Entertainment
  • Non-profit
  • Technology
  • Books
ncarol.com

Curtana Pharmaceuticals Signs Development and Manufacturing Agreement with Catalent for Brain Cancer Drug CT-179
ncarol.com/10127242

Trending...
  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart
  • Streamlining Seasonal Shutdowns: SPX FLOW Ensures Operational Continuity
  • New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
Curtana Pharmaceuticals
AUSTIN, Texas - ncarol.com -- Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that it has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana's CT-179, a drug therapy for the treatment of glioblastoma (GBM), medulloblastoma (MB), and other brain cancers.

CT-179 is a highly potent and selective small molecule inhibitor of OLIG2, a transcription factor that is essential to normal early brain development but is not actively expressed in most normal adult brain cells or in normal tissues outside the brain. However, it is expressed in all diffuse gliomas and it has been shown that OLIG2 drives tumor initiation, tumor growth, invasion into healthy brain tissue, and resistance to chemotherapy and radiation therapy. Studies to-date have demonstrated the viability of CT-179 to markedly prolong survival in numerous, relevant animal models of GBM, MB and other brain cancers. The drug is orally bioavailable, readily crosses the blood-brain barrier, and achieves high concentrations in the brain.

"This is a significant milestone for the company as we move into clinical trials, which are anticipated to commence in the first half of 2022," said Gregory Stein, M.D., M.B.A. and Chief Executive Officer, Curtana Pharmaceuticals. "GBM is a devastating disease with a poor prognosis and a variety of therapeutic challenges. We are excited to bring this easy-to-use oral therapy with the potential to improve quality of life and prolong survival of patients with GBM and other devastating brain cancers."

More on ncarol.com
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Scott Burton Releases Chaos: The Weight of a Memory, a Poetic Journey Through What Still Lingers
  • The Business Hyve Opens Waitlist for Groundbreaking Community Built for Small Business Success

Formulation development and CGMP manufacturing of the clinical trial product will take place at Catalent's 98,000 square-foot facility in San Diego, CA. This facility offers an array of services that support oral and injectable dosage forms that include preformulation testing, formulation and analytical development, CGMP manufacturing, clinical packaging, labeling, and worldwide distribution.

"Catalent is proud to partner with Curtana in the pursuit of a treatment for brain cancer," said Bryan Knox, General Manager of Catalent San Diego. "The Catalent team in San Diego is focused on early-stage development of small molecule and peptide drug candidates, from the bench to the clinic, and our expertise in oral delivery makes us an ideal partner for Curtana on the further development of CT-179."

About CT-179

FDA Orphan Drug designation for the treatment of malignant gliomas, including glioblastoma (GBM), was granted to CT-179 in August 2017. FDA Rare Pediatric Disease Designation for the treatment of medulloblastoma was granted to CT-179 in September 2020. The drug is orally bioavailable, readily crosses the blood-brain barrier, achieves very high concentrations in the brain, and significantly prolongs survival in animal models of brain cancer. CT-179 represents a novel agent which selectively targets OLIG2-expressing brain cancer cells in preclinical studies with great potential as an adjunctive therapy in the treatment of GBM, MB, and other brain cancers. An investigational new drug (IND) application filing is planned for the first half of 2022.

More on ncarol.com
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)

About Curtana Pharmaceuticals

Curtana Pharmaceuticals, founded in 2013, is a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, and other anonymous investors. In 2014, the company was awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Curtana focuses on the development of novel first-in-class, small molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma, medulloblastoma, and other brain cancers. For more information, visit www.curtanapharma.com.

Contact
Gregory Stein, M.D., M.B.A
***@curtanapharma.com


Source: Curtana Pharmaceuticals
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
  • Gastonia Pediatric Associates Welcomes Charlene Guffey, FNP-C, to Expanding Medical Team
  • databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Anthony B. Bonapart Featured on the Cover of Entrepreneurs in the Spotlight Magazine
  • Dr. Nima Missaghian to join Carolina Surgical Arts in Greensboro, NC
  • Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
  • Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
  • Suzanne Harp named Managing Director in Texas, USA
  • $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
  • Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
  • This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
  • An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart
  • Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
  • New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
_catLbl0 _catLbl1

Popular on ncarol.com

  • RNHA Named Official Community Partner of the First Annual CPAC Latino 2025 - 115
  • Real Estate CEO Launches Explosive New Book After $275,784 Wire Fraud Incident
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
  • $750 Million Market Projected to Reach $3.3 Billion Globally in 2034 for New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharma, Inc
  • JU Miner Launches Free Mining: Bitcoin, Dogecoin, and Litecoin
  • Scott Burton Announces Chaos: Volume 1 – A Journal of Being Human
  • Pregis Empowers Foam-in-Place Customers to Fight Water Insecurity with Inspyre Film
  • June 2-8 is Medicare Fraud Prevention Week
  • Shelter Structures America Appoints Shannon Heller as New Inventory Manager, Bolstering Operational Excellence in the Commercial Tent Industry
  • Fusion Marketing Group Celebrates 15 Years of Transforming Healthcare Recruitment Marketing

Similar on ncarol.com

  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Gastonia Pediatric Associates Welcomes Charlene Guffey, FNP-C, to Expanding Medical Team
  • Dr. Nima Missaghian to join Carolina Surgical Arts in Greensboro, NC
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute